Integral Diagnostics's FY 2026 Result Misses Consensus Hopes
Dow Jones
Aug 10
0000 GMT - Pathology services provider Integral Diagnostics's preliminary result for FY 2026 looks disappointing. Integral signaled annual revenue of A$788 million-A$790 million. That fell short of consensus hopes for A$799 million. Operating Ebitda of A$164 million-A$165 million missed market expectations for A$169 million. "While we had flagged downside risks to consensus numbers in our preview note, we expect the operating miss to be taken negatively by the market," says RBC Capital Markets. It had an outperform call and A$2.85/share price target on Integral entering this week. Integral ended Friday at A$2.18.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.